AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$AQST

Barber Daniel sold $120K of AQST

Barber Daniel (President and CEO) sold 25,000 shares of Aquestive Therapeutics, Inc. (AQST) at $4.82 ($0.12M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Barber Daniel
Published Sep 16, 2026, 6:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 6:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AQST
Neutral
high confidence
Mentioned
$AQST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

The disclosed sale is small relative to total holdings and market cap, offering little actionable insight.

02

Market read

Minor insider transaction with negligible effect on AQST's price or sector sentiment.

03

What to watch

Potential upcoming clinical data releases could change the relevance of the insider's holdings.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-16

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan sale is a routine, pre‑arranged trade.

Company-level read

Ticker impact

$AQSTNeutralHigh confidence
Context

President and CEO Daniel Barber sold 25,000 shares for $120,487 via a 10b5‑1 plan, reducing his stake to 652,317 shares.

Expected impact

Minimal impact; price likely unchanged.

Evidence & confidence

The transaction size is under $1M and represents a routine 10b5‑1 sale by a top executive, which markets typically view as non‑material.

Market effects

Sector

No immediate sector impact; biotech peers unlikely to be affected.

Regional

US market only; no regional ripple.

Global

Limited to investors tracking AQST.

Counterpoint

What could challenge this read

If the insider had significant confidence, the sale could signal concerns, but the 10b5‑1 plan suggests pre‑planned execution.

Key entities

  • Executive
    Daniel Barber

    President and CEO of Aquestive Therapeutics, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AQST insider trading history →

Related articles

SEP 8
$AQSTMed

Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.

insidermonkey.com3 min
AUG 19
$AQSTMed

Aquestive (AQST) Q2 2026 Earnings Call Transcript

Aquestive (AQST) reported progress in its Anaphylm resubmission to the FDA, addressing previous issues with packaging and administration. The company's recent studies showed significant improvements in ease of use and effectiveness. Aquestive aims to resubmit Anaphylm before the end of the quarter and believes the product has a strong market opportunity, potentially exceeding $1 billion annually, due to its clinical differentiation and ease of use.

yahoo.com7 min
AUG 12
$AQSTMed

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics (NASDAQ:AQST) reported Q2 revenue of $13.8M, up 38% year over year, and a net loss of $22.9M ($0.18/share). Excluding a $11.7M debt-extinguishment loss, net loss was $11.2M. The company discussed FDA resubmission review timing for Anaphylm, cash of $98.5M, and maintained 2026 guidance of $46M to $50M revenue.

yahoo.com7 min
AUG 11
$AQSTMed

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film • Remains on track to resubmit Anaphyl

SEC EDGAR 8-K4 min
AUG 10
$AQSTMedAI 8/10

Why is Aquestive Therapeutics stock surging today?

Aquestive Therapeutics (AQST) shares rose about 9.4% pre-open after the company reported positive topline results from two pivotal studies for its Anaphylm (dibutepinephrine) sublingual film. The data address FDA concerns from a January 2026 Complete Response Letter and the company said its NDA resubmission remains on track for Q3 2026.

investing.com3 min
AUG 10
$AQSTMed

Aquestive Reports Positive Human Factors and PK Results for Anaphylm, Plans NDA Resubmission Q3 2026

Aquestive Therapeutics (AQST) reported positive human factors and PK topline results for Anaphylm, including faster median pouch open time (17s to 3s) and fewer opening and placement errors. PK Cmax was comparable vs clinician dosing (391.7 vs 357.6 pg/mL) with median Tmax 12 min. No serious adverse events were reported. Aquestive plans to resubmit the NDA in Q3 2026.

tradingview.com1 min